Initial digest — GHRHR receipt

what this node claims

Initial digest — GHRHR

AlphaFold v6 prediction landed for **GHRHR** (Growth hormone-releasing hormone receptor). UniProt accession: `Q02643`. Lane: `metabolic`. Mean per-residue pLDDT: **75.82**. Sermorelin / tesamorelin / CJC-1295 target.

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

75.8

423 residues / min 30.53 / max 97.0 / source alphafold db

Very high 26.5% 112 residues / >=90

Confident 41.4% 175 residues / 70-89

Low 20.1% 85 residues / 50-69

Very low 12.1% 51 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 423 of 423 residues.

residues 393-423 / mean 40.48
residues 1-29 / mean 39.9
residues 313-328 / mean 60.18
residues 343-358 / mean 63.55

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — GHRHR